NVO - Novo Nordisk A/S

NYSE - NYSE Delayed price. Currency in USD
46.84
+0.44 (+0.95%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous close46.40
Open46.85
Bid0.00 x 3200
Ask48.42 x 4000
Day's range46.41 - 47.00
52-week range41.03 - 58.37
Volume2,060,678
Avg. volume1,498,233
Market cap114.533B
Beta0.82
PE ratio (TTM)19.13
EPS (TTM)2.45
Earnings dateN/A
Forward dividend & yield1.28 (2.76%)
Ex-dividend date2018-03-23
1y target est60.40
Trade prices are not sourced from all markets
  • 5 Biggest Blockbuster Diabetes Drugs of the Future
    Motley Fool14 hours ago

    5 Biggest Blockbuster Diabetes Drugs of the Future

    The diabetes market is growing rapidly. These drugs -- and drugmakers -- should be the biggest winners.

  • Bloombergyesterday

    Novo Says Tresiba Shows Significantly Better Blood Sugar Control

    Novo Nordisk A/S said its diabetes treatment Tresiba showed “significantly improved” blood sugar control and lower rates of hypoglycemia compared with insulin glargine U300 in real-world evidence study....

  • Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
    Zacks2 days ago

    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

  • Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study
    Zacks3 days ago

    Novo Nordisk's (NVO) Oral Ozempic Positive in Diabetes Study

    Novo Nordisk (NVO) announces positive headline results of two phase III studies PIONEER oral formulation of Ozempic (semaglutide) as a treatment for adults with type II diabetes.

  • Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
    Zacks4 days ago

    Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

    Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

  • LLY vs. NVO: Which Stock Should Value Investors Buy Now?
    Zacks4 days ago

    LLY vs. NVO: Which Stock Should Value Investors Buy Now?

    LLY vs. NVO: Which Stock Is the Better Value Option?

  • Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming
    Motley Fool7 days ago

    Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming

    Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?

  • Reuters17 days ago

    Novo Nordisk shares fall after report of layoffs

    Shares in Novo Nordisk (NOVOb.CO) opened down 4 percent on Friday after a media report citing anonymous sources said the world's biggest diabetes drug company mulls axing up to 3,000 staff and dropping its long-term financial targets. Denmark's Novo Nordisk said in May that the new rules would cut its 2019 sales by 1-2 percent but kept its long-term operating growth forecast of 5 percent. According to Danish daily Borsen, the firm is now considering ditching the long-term target due to "uncertain and unpredictable markets".

  • Analyzing Novartis’s Revenue in Q1
    Market Realist24 days ago

    Analyzing Novartis’s Revenue in Q1

    In the first quarter, Novartis’s (NVS) revenue grew 10% to ~$12.7 billion from ~$11.5 billion. As we discussed in the previous part, it reported EPS of $1.28, meeting analysts’ estimate. Its revenue of ~$12.7 billion surpassed analysts’ estimate of ~$12.6 billion, marking ~10% YoY (year-over-year) growth.

  • Top Diabetes Stocks to Buy Today
    Motley Fool24 days ago

    Top Diabetes Stocks to Buy Today

    More people than ever are being diagnosed with diabetes, and big advances in treatment could make these diabetes stocks savvy investments.

  • Novo Nordisk's Oral Ozempic Positive in Diabetes Study
    Zacks25 days ago

    Novo Nordisk's Oral Ozempic Positive in Diabetes Study

    Novo Nordisk's (NVO) oral formulation of Ozempic acts better in lowering blood sugar levels in adults with type II diabetes than Eli Lilly's Jardiance, in the second phase IIIa study, PIONEER 2.

  • How to Invest in Diabetes Stocks
    Motley Foollast month

    How to Invest in Diabetes Stocks

    Here's everything you need to know about investing in the fast-growing diabetes market.

  • MarketWatchlast month

    Almost a quarter of the world’s population will be obese by 2045

    Obesity is a global epidemic. Nearly one-quarter (22%) of the people in the world will be obese by 2045, up from 14% in 2017, and one in eight will have type 2 diabetes, up from 9% in 2017, it concluded. Using a World Health Organization database and dividing each country’s population into age groups, the authors suggest that — in order to stabilize the rate of global diabetes at 10% — obesity rates must fall from the current level of 14% to 10% by 2045.

  • Top Research Reports for Walmart, AT&T & Novo Nordisk
    Zackslast month

    Top Research Reports for Walmart, AT&T & Novo Nordisk

    Top Research Reports for Walmart, AT&T & Novo Nordisk

  • AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
    Market Realistlast month

    AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates

    AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products. Though it’s headquartered in London, England, the company reports its revenue in US dollars. The company is set to release its 1Q18 earnings on May 18.

  • Novo Nordisk Fights Payer Pressure With New Meds
    Motley Fool2 months ago

    Novo Nordisk Fights Payer Pressure With New Meds

    Sales of older medications are on the decline, but newer medications helped the revenue line grow at constant exchange rates.

  • Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Novo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript

    NVO earnings call for the period ending March 31, 2018.

  • NVS and NVO: Which Has Higher Upside Potential?
    Market Realist2 months ago

    NVS and NVO: Which Has Higher Upside Potential?

    Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1. The stock is trading at a forward PE (price-to-earnings) ratio of 13.3, and its PEG (price-to-earnings-to-growth) ratio is 2.2. At present, Novartis’ price-to-sales ratio is 3.6, and its price-to-book ratio is 2.4.

  • These Pharma Stocks Offer the Most Upside Potential
    Market Realist2 months ago

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility. While the S&P 500 has recovered a bit from its fluctuation this year and has fallen only 0.12% year-to-date, the iShares US Pharmaceuticals ETF (IHE), SPDR S&P Pharmaceuticals ETF (XPH), VanEck Vectors Pharmaceutical ETF (PPH), and First Trust NASDAQ Pharmaceuticals ETF (FTXH) have fallen 4.4%, 5.9%, 3.5%, and 2.5%, respectively, indicating that pharma stocks are underperforming the overall market.

  • Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
    Zacks2 months ago

    Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss

    Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.

  • Reuters2 months ago

    Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook

    Denmark's Novo Nordisk (NOVOb.CO), the world's biggest maker of diabetes drugs, reported first-quarter operating profit above expectations on Wednesday and raised the lower end of its 2018 sales and profit forecast. Operating profit fell 8 percent to 12.4 billion Danish crowns (1.5 billion pounds) in the January to March quarter compared with a year ago, hit by the depreciation of the U.S. dollar, but beat an average 11.8 billion crown forecast in a Reuters poll of analysts. With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once-weekly injection and tablet version of its semaglutide drug.

  • GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business
    Market Realist2 months ago

    GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business

    GlaxoSmithKline’s (GSK) Consumer Healthcare business includes various products for oral health, wellness, nutrition, and skin health. The consumer healthcare business reported revenues of ~2.0 billion pounds in 1Q18, a ~3% decrease compared to 1Q17.

  • GlaxoSmithKline’s Pharmaceutical Business in 1Q18
    Market Realist2 months ago

    GlaxoSmithKline’s Pharmaceutical Business in 1Q18

    GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products. The Pharmaceuticals business segment reported revenues of ~4.0 billion pounds in 1Q18.

  • Analyst Recommendations for Novo Nordisk in April
    Market Realist2 months ago

    Analyst Recommendations for Novo Nordisk in April

    In March, Novo Nordisk (NVO) received an exclusive worldwide license for EpiDestiny’s sickle cell disease program, EPI01. Novo Nordisk will pay more than $400 million as an upfront payment to EpiDestiny for the license. EpiDestiny will also receive development and sales milestone payments from Novo Nordisk along with royalties on net sales of the product.

  • How Is Novo Nordisk Positioned before 1Q18?
    Market Realist2 months ago

    How Is Novo Nordisk Positioned before 1Q18?

    In 4Q17, Novo Nordisk (NVO) generated revenues of 28 billion Danish kroner, which is a ~2% decline on a YoY (year-over-year) basis.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes